GlassScriptPhysician profile
James David Cook
NPI 1154093748
$1,215.70
in general payments reported to CMS, 2019-2025
21 companies · $665 in 2025
The $665 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $211 · 2024: $340 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $196.63 | 2023-2025 | |
| Novo Nordisk INC | $194.13 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Viiv Healthcare Company | $170.07 | 2025 | Apretude, Cabenuva, Rukobia |
| Astrazeneca Pharmaceuticals LP | $113.29 | 2023-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $58.45 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $57.76 | 2024-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $47.09 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $43.20 | 2023 | Quviviq |
| Amgen INC. | $40.84 | 2025 | Repatha |
| Gilead Sciences, INC. | $39.79 | 2025 | |
| Xeris Pharmaceuticals, INC. | $32.97 | 2025 | Keveyis |
| Abbvie INC. | $28.47 | 2023 | |
| Baxter Healthcare | $27.61 | 2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Paratek Pharmaceuticals, INC. | $25.38 | 2025 | Nuzyra |
| Organon LLC | $24.95 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.43 | 2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $21.93 | 2024 | |
| Dexcom, INC. | $20.39 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $18.56 | 2024 | Shingrix, Arexvy |
| Astellas Pharma US INC | $15.70 | 2024 | Veozah |
| Lilly USA, LLC | $14.06 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.